ROCKVILLE, Md., Sept.
30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a
leading clinical-stage biotechnology company seeking to improve
lives through the curative potential of gene therapy based on its
proprietary NAV® Technology Platform, today announced
that it will present at the Chardan 3rd Annual Genetic
Medicines Conference on Monday, October 7,
2019, at The Westin New York Grand Central, NY:
Panel: Emerging Disease Areas in Gene Therapy;
Monday, October 7, 2019 at
9:30 a.m. ET
Fireside Chat: Monday, October 7, 2019 at 12:00 p.m. ET.
A live webcast of the fireside chat can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the fireside chat webcast will be available on
the same website for approximately 30 days following the
presentation.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
CONTACT:
Tricia
Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Heather
Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen,
212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-chardan-3rd-annual-genetic-medicines-conference-300927368.html
SOURCE REGENXBIO Inc.